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Abstract
Background: Oropharyngeal candidasis is a common opportunistic infection seen in immunocompromised
patients. Fluconazole has a broad spectrum antifungal activity including a wide variety of candida species. Aim of
the present investigation was to formulate and find out the relative efficacy of in situ gels of fluconazole.
Method: The in situ gels were prepared using polymers which exhibited sol-to-gel phase transition due to change
in specific physico-chemical parameters, such as ion triggered system using gellan gum (0.5% w/v) along with
sodium carboxylmethylcellulose (0.35%w/v). The study design was bicenter, ‘pseudo-randomised, single blind trial
conducted in Mangalore., India, which includes 15 HIV positive patients, 15 patients with partial or completes
dentures, and 15 patients who were treated with (active control) fluconazole tablets 100 mg/day for 14 days.
Severity of disease was scored clinically before treatment and at clinical evaluations on day 3, 7, 14, 18, 21, 35, and
42. Semiquantitative microbiological cultures of oral swabs were also obtained on same days.
Results: All patients had mycological documented oropharyngeal candidiasis and were treated with fluconazole
(0.5%w/v) in situ gels for 14 days Severity of disease was scored clinically before treatment and at different
predetermined time intervals along with semi quantitative culture of oral swabs. The clinical response rate showed
97% cure after 14 days in the treated with in situ gel. In comparison, the control group treated with fluconazole
tablets showed 85% improvement in symptoms of oral candidiasis. The patients suffering from HIV infection
showed relapse in oral candidiasis at the end of 21 days. The patients having oral candidiasis due to partial or
complete dentures showed complete recovery and were free from signs and symptoms of oral candidiasis.
Conclusions: The in situ gel formulation of fluconazole was well tolerated with no severe adverse reaction and
offers a better alternative to tablet formulation in the treatment of oropharyngeal candidasis.
Trial registration: Current Controlled Trails ISRCTN90634047
Background
Fungal pathogens increasingly cause nosocomial infec-
tions, especially among the surgical patients and the
high risk critically ill, with an attributable death rate
estimated at 38% [1]. Local delivery of drugs to the tis-
s u e so ft h eo r a lc a v i t yh a san u m b e ro fa p p l i c a t i o n s
including the treatment of toothache, periodontal dis-
eases, dental caries, bacterial and fungal infections. The
conventional formulations for the local delivery of drugs
to the oral cavity are the mouth paints, rinses, troches,
creams, oral tablets and suspensions. But limitations
include, poor bioavailability, poor availability of drug at
the site of action and patient compliance. One way to
improve the efficacy of the dosage form is to deliver the
antifungal agent locally in the oral cavity [2,3] on the
effected site. Better stability and longer residence time
of locally administered antifungal agent will allow better
penetration through the oral mucosal layer to act on
Candida species.
In situ gels can resist the physiological stress caused
by the skin flexion, mastication and movement of ton-
gue, adopting shape of the applied area and controlling
* Correspondence: harishnayari@gmail.com
1Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences,
Paneer, Deralakatte Post, Mangalore, India
Full list of author information is available at the end of the article
Nairy et al. Trials 2011, 12:99
http://www.trialsjournal.com/content/12/1/99 TRIALS
© 2011 Nairy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the drug release for prolonged time. Fluconazole is an
orally active bistriazole antifungal agent which is used in
the treatment of superficial and systemic candidasis [4].
The present dosage regimen of fluconazole for the treat-
ment of oropharyngeal candidasis (OPC) of 100 mg
tablets of fluconazole tablet twice daily. The occurrence
of OPC in patients deteriorates the oral mucosa;
increases pain, dysphagia, and anorexia; alters taste; and
contributes toward worsening nutritional and general
status. Recurrence of infection is usually seen in
approximately 33% of patients treated with tablet formu-
lation of fluconazole. Thus, there is a need for a topical
agent which is as effective as systemic agent upon single
administration, well tolerated and would not increase
the risks of emergence of resistance [5]. Rene-jean Ben-
sadown et al., demonstrated the ability to deliver high
and prolonged salivary concentration of 50 mg mucoad-
hesive buccal tablets of miconazole helped in reduction
of dose, reduced the risk of systemic exposure, drug-
drug interaction and other toxicity [6].
In view of eliminating the signs and symptoms of OPC,
present study was focused on formulation of in situ gels
of fluconazole and evaluatedf o ri t sp h y s i c o - c h e m i c a l
properties as well as in vivo efficacy in patients.
Objectives
The primary objective of study was to assess efficacy of
topical application of in situ gels of fluconazole for the
treatment of oropharyngeal candidiasis. The secondary
objective of this study was to assess the microbiological
colony count from the baseline to the end of the follow
up term.
Methods
Materials
F l u c o n a z o l ew a sag i f ts a m p l ef r o mM / sD e eP h a r m a
Ltd., New Delhi, India. Gellan gum was procured from
Hi-Media Pvt. Ltd, Mumbai, India. All other materials
were used of analytical grade. Sub cultures of Candida
Spp.w e r eo b t a i n e df r o mM T C C (Microbial Type Cul-
ture Collection), Chandigarh, India.
Preparation of in situ gelling system
Gellan gum solutions of 0.5%w/v was prepared by add-
ing the gum to deionized water containing 0.17%w/v
sodium citrate and heated up to 90°C with continuous
stirring. After cooling below 40°C an appropriate
amount of calcium chloride (0 . 0 5 % w / v )w a sa d d e di n t o
the sol. Fluconazole (0.5%w/v) was dissolved in water
and added to the above solution. The mixture was sha-
ken using magnetic stirrer under aseptic condition to
ensure thorough mixing. The composition of formula-
tion under study is shown in Table 1. The formulation
and characterization of the in situ gels has earlier
reported [7]. The concentration of 0.5%w/v of flucona-
zole was taken based on Minimum inhibitory concentra-
tion (MIC) to show antifungal activity.
Characterization of the in situ gels
The prepared gels were subjected for different para-
meters such as gelling capacity, viscosity measurement
of both sols as well as corresponding gels, gel strength,
mucoadhesive force, spreadability in situ, release studies,
in vitro antifungal studies and in vivo evaluation.[7,8]
In situ release studies
In situ release studies were carried out using, a “flow
through cell” Dissolution medium pH 6.8 (simulated
salivary pH) was pumped at a flow rate of 0.6 ml/min
(corresponding to mean resting salivary flow rate) using
flow regulators. Sols were added from the top, so that
upon contact with the simulated salivary fluid the transi-
tion took place from sol to gel. The gels settled on the
mucous membrane with mucoadhesion. Samples of 2
ml were withdrawn at different time intervals from the
reservoir till the gel completely eroded. The cumulative
percent drug released was determined by measuring the
absorbance at 260 nm.
In Vitro antifungal studies
The antifungal efficacy onof in situ gel formulation on
Candida Spp. was determined by agar diffusion method
employing ‘cup plate technique’. Sterile solutions of flu-
conazole in water and the developed gel having the pH
adjusted to 7.0, were poured into cups (0.1 ml of 0.1%
w/v) bored into sterile malt yeast agar previously seeded
with test organism. After allowing diffusion of the solu-
tions for 2 h, the agar plates were incubated at 37°C for
24 h. The zone of inhibition (ZOI) was measured
around each cup was compared with that of pure drug.
The entire operation was carried out under aseptic con-
dition in triplicate. Both positive and negative controls
were maintained during the study [9].
Table 1 In vitro characterization of in situ formulation
Formu-ation pH* Viscosity*
(cps)
Spreadibility
g.cm/s
Drug Content
(%w/w)
*Muco-adhesive force
dynes/cm
2
Gelling
Capacity
Gel strength
g/s
F1 7.2 14000 28.5 90.4 52.5 ± 7.5 +++ 6.5
* Average of three reading
- No gelation; + Gel after few minutes, dissolved rapidly; ++ Gelation immediately, remains for few hours; +++ Gelation immediately, remains for extended
period.
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Selection criteria of Patients
A. Inclusion criteria . Patients of either sex (age group
of 18 or above), with HIV-antibody seropositive or with
partial or complete denture and the clinical picture of
oropharyngeal candidiasis, which is characterized by
creamy, white, curd like patches, removable erythema-
tous lesions on the oral mucosal surfaces. On direct
microscopic examination of samples of these infectious
patches must reveal the presence of candida Spp., con-
sistently and further must get confirmed the presence of
mycological culture and differentiation of strains using
Hicrome
® medium is used.
B. Exclusion criteria A history of significant hepatic
abnormalities or hepatic diseases and a life expectancy
of less than 1 month or a clinical condition such that
study completion could not be assured. Patients with a
history of hypersensitivity to imidazole or azole com-
pound and also patient who required therapy with other
antifungal agents, H2-receptor blockers, antacids, rifam-
picin, phenobarbital, pheytoin, carbamazeme, terfena-
dine, or astimazole. Pregnant or lactating women were
also excluded from the study.
The study protocol was approved by institutional
review board and each patient signed a written state-
ment of informed consent prior to receiving the study
medication. The clinical study protocol was approved by
the Institutional Human Ethics Committee (Approval
No: ABSM/EC/18/2008)
Study design
A bicenter, open-label, single blind, pseudo-randomised
clinical trial design was followed, to compare the effi-
cacy of fluconazole in situ gel (0.5% w/v) with that of
fluconazole tablets (100 mg) for 14 days. The patients
with OPC were divided into 3 groups, each comprising
of 15 patients. Group I comprised of patients having
HIV/AIDS treated with in situ gel, Group II comprised
of patients with partial or complete dentures, treated
with in situ gel and group III were comprised of patients
with HIV/AIDS treated with fluconazole tablets 100 mg
for 14 days. The patients demographic and baseline
characters are shown in table 2.
Following the initial (base line) visit, the subsequent
visits were scheduled on day 3, 7, 14, 18, 22, 34, and 44.
T h ee f f i c a c yo ft h ed o s a g ef o r mw a sc o m p a r e dw i t h
tablets for the successful clinical response and changes
from baseline for the symptoms of OPC, which included
the soreness erythema, extent of oral lesions and quanti-
fication of colony forming units (CFU) of Candida spp.
Clinical assessment were made and recorded by a Regis-
tered clinical practitioner. The severity of baseline,
symptoms was assessed on a scale of 0 to 3 (0 = absent,
1 = mild, 2 = moderate, 3 = severe). The baseline
severity of signs and symptoms of OPC are given in
table 3. The quantification of CFU of Candida spp., was
done by taking oral swabs at three different locations.
Oral swabs were then streaked on Hichrome
® medium.
The specimen was examined microscopically for hyphae,
color of colony to distinguish the strain.
Clinical efficacy evaluation
The primary efficacy parameter for clinical response was
rated according to the change in signs and symptoms
from the baseline. The assessment was rated as “cured”
(clearance of all signs and symptoms), “improved” (mini-
mal signs and symptoms with no residual visible candida
lesions), unchanged (no change in signs and symptoms),
or “deteriorated” (worsening or increasing signs and
symptoms). Patients with a clinical evaluation of “cured”
or “improved” were considered as a successful outcome
of the study.
Secondary efficacy parameters included the quantifica-
tion in terms of CFUs of Candida spp. and results of
culture from swabs taken at the same sites used at base-
line. A mycological cure was defined as a yeast quantifi-
cation of <10 CFU/ml based on comparison of
mycological culture from swabs collected from healthy
volunteers.
To analyze the data of clinical efficacy statistically, a
two-factor repeated measures analysis of variance was
used between the treated groups over a period of 44
days. The criterion for significance was set at p < 0.05.
Table 2 Patient demographic and base line
characteristics
Variable Treatment group Total
Fluconazole
treated
group with
HIV
Fluconazole treated
group with partial or
complete dentures
Active
control
Gender,
number
Male 10 8 7 25
Female 05 5 8 20
Age
Mean ± S.D 32 ± 3.5 45 ± 4.5 35 ± 1.5
CD4 Count/
mm
3
Mean ± S.D
172 ± 78 650 ± 150 200 ± 250
Pre
treatment
culture
Candida
albicans
12 10 13
Candida
Parapsilosis
-0 1 -
Candida
Dubliniansis
03 04 02
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Sol to gel transformation of gellan occurs in the pre-
sence of either monovalent or divalent cations in con-
tact with the salivary fluids. The quantities of the
complexing agents calcium chloride and sodium citrate
must be such that there is no free calcium in ionic form
in the formulation so as to ensure that they are in fluid
state before administration, but sufficient Ca
++ ions
must be released when the complex is broken down
(due to dissociation) in presence of simulated salivary
fluid to cause gelation. It was reported earlier that opti-
mum concentration of calcium chloride (0.05%w/v) with
0.17% w/v sodium citrate is used along with gellan gum
(0.5%w/v) were found to be satisfactory to cause gelation
and gelling capacity. Aqueous sols exhibited pH value of
7.2 at 25°C (Table 1). The formulation exhibited shear
thinning pseudo-plastic behavior with thixotrophy.
Further, it was also found that, the formulations were
liquid at room temperature (25°C) with viscosity of 85
cps which underwent rapid gelation when the pH was
raised to 6.8 which contributed to the increased viscos-
ity of 14000 cps. The mucoadhesive force is an impor-
tant physicochemical parameter for topical application
in buccal cavity which was found to be 55 dynes/cm
2.
The values are shown in table 1
In vitro drug release
The in vitro release of drug from these gels was charac-
terized by an initial phase of high release (burst effect).
However, as gelation proceeds, the remaining drug was
released at a slower rate followed by a second phase of
moderate release. The formulations showed sustained
release up to 8 h. At the end of 8 h 98% drug was
released from the formulation.
In vivo evaluation
A total of 45 patients which included 15 patients who
were HIV positive, 15 patients with partial or complete
dentures, and the third group consisted of 15 patients
with HIV positive patients treated with fluconazole
tablets. All patients were confirmed of oropharyngeal
candidiasis.. A 5 ml of the dosage form was administered
every 12 h for a period of 14 days at the infected area
using syringe. The dosage form upon contact with saliva
formed gel (within >4 s) and was visible for a period of 6
to 8 h. At the end of the treatment phase, the clinical
response rate was assessed. From group I, 12 out of 15
patients (80%) showed good clinical response up to a per-
iod of 21 days. After which the relapse were seen in 90%
cases having HIV. It was considered as “cured” for a per-
iod of 21 days for this group. Whereas the group II, the
clinical efficacy “cured” were seen in 15 out of 15 patients
(100%) and relapse were not seen up to 44 days. It was
considered as “cured” for group II for a period of 44 days
(study duration). In group III, 10 out of 15 patients
(66.6%) were “cured” at the end of 14
th day, whereas at
the end of 18
th day showed relapse in 8 out of 10 (80%)
“cured” cases. The other patients did not show any clini-
cal response and no change from baseline.
The microbiological investigation at baseline, all the
treated groups showed positive microscopic result for
OPC. At day 14, that is at the end of the treatment the
percentage of subjects with a negative microscopic
examination increased to approximately 85%, 95% and
75% for group I, II and III respectively from the base-
line. During the follow-up period, the microbiological
investigation was done to understand the relapse in
O P C ,w h i c hs h o w e dt h a ta tt h ee n do f4 4
th day the
g r o u pIh a sa ni n c r e a s ei np o s itive microscopic results
(100%), whereas in group II no changes and in group III
there was increase in CFUs (300/ml) in 100% cases
which showed negative at the end of 14
th day, indicating
relapse thereafter. (Figure 1). The most common species
isolated was Candida albicans (30 out of 45 cases)
strains.
Table 3 Comparison of disease severity at baseline and at the end of the study period
Parameter Group I Group II Group III Group I Group II Group III P Value
At day 0 (Baseline) At day 44 (end of study period)
Extent of Lesion 1.03 ± 0.01 0.2 ± 0.02 1.13 ± 0.01 0.94 ± 0.02 0.01 ± 0.00 1.11 ± 0.01 0.36
Soreness/Burning 0.36 ± 0.05 0.13 ± 0.06 0.56 ± 0.05 0.46 ± 0.05 0.03 ± 0.00 0.66 ± 0.05 0.39
Erythema 0.93 ± 0.07 0.35 ± 0.01 1.03 ± 0.07 0.96 ± 0.05 0.00 ± 0.00 0.98 ± 0.07 0.42
Group I Group II Group III
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Figure 1 Comparative microbiological studies in terms of
colony forming units for oral swabs at the end of 44 days.
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Oral candidiasis threatens all kinds of immunocompro-
mised patients and may recur repeatedly during the
course of their underlying disease. Topical agents gener-
ally have been used in the early stages, where as sys-
temic therapy is limited to patients with poor tolerance.
In the present investigation in situ gels of fluconazole
was formulated and evaluated for the in vitro and in
vivo characteristics. It is established that formulations
containing calcium carbonate produce a significantly
produced stronger gel than those containing sodium
bicarbonate. This is due to the internal ionotropic gela-
tion effect of calcium on gellan gum [7,8]. The present
investigation utilized Ca
++ ions in complexed form with
sodium citrate (0.17%w/v) which upon contact with the
saliva formed gel which would release the drug for a
longer duration of time. The slightly acidic conditions of
the buccal cavity ensured reproducible gelation of the
gellan gum. Low level of cations present in the solution
was sufficient to hold the molecular chains together and
inhibit hydration. A reduction in the concentration of
gellan gum without compromising the gelling capacity
and rheological properties of the delivery system may be
achieved by the addition of viscosity enhancing polymers
such as sodium carboxylmethylcellulose (NaCMC). Since
NaCMC helped the gel to rapidly settle because of its
higher density, the gels showed better adhesion property
to the mucous membrane and subsequently prolonged
release. The formulation showed optimum pH of 7.0 ±
0.3 which is very essential to reduce irritation. The for-
mulation showed good sol to gel conversion with low
viscosity of the sols and subsequent gels showed higher
viscosity. The higher viscosity could contribute in better
mucoadhesive property and retentive property. The in
vitro release profile was conducted for a period of 6 h
and showed biphasic release pattern which is a charac-
teristic feature of matrix diffusion kinetics. The initial
burst effect was considerably reduced with increase in
polymer concentration.
In vivo evaluation showed that all the three groups
showed good clinical response during the treatment dura-
tion (14 days). Group I, group II and group III showed
clinically cured for 95%, 98% and 93% of the patients
respectively. During the follow up the patients treated
with fluconazole tablets showed higher incidence of
relapse at faster rate (within 18 days). The group II
patients did not show any signs of relapse for a period of
44 days. No statistically significant differences between dif-
ferent treated groups were observed in the clinical
response during the treatment period. The faster relapse
were seen in patients treated with oral tablets was may be
due to lower drug concentration at the site of infection. C.
albicans was cultured in more than 66.6% in all treated
groups. Because of immunosupression in HIV patients,
>90% of the cases showed relapses at the end of 21 days
and remained “unchanged” which was same in case of
group III, Significant clinical efficacy was seen in patients
of group II with no relapse and the patients were clinically
“cured”. A comparison of various treated groups of
patients free from OPC is given in Figure 2. Bonferroni’s
Multiple Comparison Test studies showed no significant
difference in clinical response (P < 0.005) between the
treated groups at the end of 14 days. But the significance
did not persist after 22 days between treated groups.
Microbiological investigation revealed a statistically signifi-
cant difference (P > 0.001) when the different treated
groups were compared for a period of 14 days. In situ gels
were more effective than fluconazole tablets in producing
greater rates of negative culture and better clinical
response. The more conventional method of assessing
mycological response-negative culture demonstrated a sig-
nificant difference in the ability of In situ gels to eradicate
Candida species at the end of therapy when compared
with fluconazole tablets. The results of the in vivo evalua-
tion demonstrated that fluconazole in situ gels for 14 days
(0.5%w/v) was effective in treating of oral candidiasis with
patients suffering from HIV/AIDS and with partial or
complete dentures. In situ gels were well tolerated by the
patients in the trails. Adverse events reported in the litera-
ture tend to be relatively minor and usually related to the
gastrointestinal tract [10,11]. The finding was confirmed
in our study as well. Gastrointestinal symptoms (eg, nau-
sea, diarrhea, abdominal pain) were experienced by
approximately 6 patients in the treated groups.
Conclusion
In conclusion, the in situ gel formulation of fluconazole
has shown significant clinical efficacy in the treatment
of oropharyngeal candidiasis and produced successful
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of candidal infection.
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Page 5 of 6clinical outcomes. The in situ gels were easier to admin-
ister, well tolerated and showed better clinical efficacy in
treatment of oropharyngeal candidiasis in patients with
partial or complete dentures or HIV/AIDS patient and
can be considered as a viable alternative to the current
conventional formulations available for the treatment of
candidiasis.
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